Literature DB >> 25622649

Fragile X-associated tremor/ataxia syndrome.

Paul J Hagerman1, Randi J Hagerman.   

Abstract

Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder that affects some but not all carriers of small, noncoding CGG-repeat expansions (55-200 repeats; premutation) within the fragile X gene (FMR1). Principal features of FXTAS include intention tremor, cerebellar ataxia, Parkinsonism, memory and executive function deficits, autonomic dysfunction, brain atrophy with white matter disease, and cognitive decline. Although FXTAS was originally considered to be confined to the premutation range, rare individuals with a gray zone (45-54 repeats) or an unmethylated full mutation (>200 repeats) allele have now been described, the constant feature of the disorder remaining the requirement for FMR1 expression, in contradistinction to the gene silencing mechanism of fragile X syndrome. Although transcriptional activity is required for FXTAS pathogenesis, the specific trigger(s) for FXTAS pathogenesis remains elusive, highlighting the need for more research in this area. This need is underscored by recent neuroimaging findings of changes in the central nervous system that consistently appear well before the onset of clinical symptoms, thus creating an opportunity to delay or prevent the appearance of FXTAS.
© 2015 New York Academy of Sciences.

Entities:  

Keywords:  CGG repeat; FXTAS; RNA toxicity; dementia; neurodegeneration; premutation

Mesh:

Substances:

Year:  2015        PMID: 25622649      PMCID: PMC4363162          DOI: 10.1111/nyas.12693

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  146 in total

Review 1.  Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders.

Authors:  John Douglas Cleary; Laura P W Ranum
Journal:  Curr Opin Genet Dev       Date:  2014-05-22       Impact factor: 5.578

2.  The effect of FMR1 CGG repeat interruptions on mutation frequency as measured by sperm typing.

Authors:  C B Kunst; E P Leeflang; J C Iber; N Arnheim; S T Warren
Journal:  J Med Genet       Date:  1997-08       Impact factor: 6.318

3.  Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation.

Authors:  Faraz Farzin; Hazel Perry; David Hessl; Danuta Loesch; Jonathan Cohen; Susan Bacalman; Louise Gane; Flora Tassone; Paul Hagerman; Randi Hagerman
Journal:  J Dev Behav Pediatr       Date:  2006-04       Impact factor: 2.225

4.  Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation.

Authors:  David Hessl; Flora Tassone; Danuta Z Loesch; Elizabeth Berry-Kravis; Maureen A Leehey; Louise W Gane; Ingrid Barbato; Cathlin Rice; Emma Gould; Deborah A Hall; James Grigsby; Jacob A Wegelin; Susan Harris; Foster Lewin; Dahlia Weinberg; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2005-11-05       Impact factor: 3.568

5.  Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation.

Authors:  David Hessl; John M Wang; Andrea Schneider; Kami Koldewyn; Lien Le; Christine Iwahashi; Katherine Cheung; Flora Tassone; Paul J Hagerman; Susan M Rivera
Journal:  Biol Psychiatry       Date:  2011-07-23       Impact factor: 13.382

6.  Expanded clinical phenotype of women with the FMR1 premutation.

Authors:  Sarah M Coffey; Kylee Cook; Nicole Tartaglia; Flora Tassone; Danh V Nguyen; Ruiqin Pan; Hannah E Bronsky; Jennifer Yuhas; Mariya Borodyanskaya; Jim Grigsby; Melanie Doerflinger; Paul J Hagerman; Randi J Hagerman
Journal:  Am J Med Genet A       Date:  2008-04-15       Impact factor: 2.802

Review 7.  The fragile-X premutation: a maturing perspective.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Am J Hum Genet       Date:  2004-03-29       Impact factor: 11.025

8.  Transmission of an FMR1 premutation allele in a large family identified through newborn screening: the role of AGG interruptions.

Authors:  Carolyn M Yrigollen; Guadalupe Mendoza-Morales; Randi Hagerman; Flora Tassone
Journal:  J Hum Genet       Date:  2013-06-06       Impact factor: 3.172

9.  Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome.

Authors:  Peng Jin; Ranhui Duan; Abrar Qurashi; Yunlong Qin; Donghua Tian; Tracie C Rosser; Huijie Liu; Yue Feng; Stephen T Warren
Journal:  Neuron       Date:  2007-08-16       Impact factor: 17.173

10.  High apolipoprotein E4 allele frequency in FXTAS patients.

Authors:  Francisca Silva; Laia Rodriguez-Revenga; Irene Madrigal; Maria Isabel Alvarez-Mora; Rafael Oliva; Montserrat Milà
Journal:  Genet Med       Date:  2013-03-14       Impact factor: 8.822

View more
  71 in total

Review 1.  Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.

Authors:  Reymundo Lozano; Veronica Martinez-Cerdeno; Randi J Hagerman
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 2.  Advanced technologies for the molecular diagnosis of fragile X syndrome.

Authors:  Flora Tassone
Journal:  Expert Rev Mol Diagn       Date:  2015-10-21       Impact factor: 5.225

Review 3.  Dendrite and spine modifications in autism and related neurodevelopmental disorders in patients and animal models.

Authors:  Verónica Martínez-Cerdeño
Journal:  Dev Neurobiol       Date:  2016-08-30       Impact factor: 3.964

Review 4.  General Anesthetic Use in Fragile X Spectrum Disorders.

Authors:  Andrew Ligsay; Marwa El-Deeb; Maria J Salcedo-Arellano; Nina Schloemerkemper; Jeremy S Grayson; Randi Hagerman
Journal:  J Neurosurg Anesthesiol       Date:  2019-07       Impact factor: 3.956

5.  Repeat-associated non-ATG (RAN) translation.

Authors:  John Douglas Cleary; Amrutha Pattamatta; Laura P W Ranum
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

Review 6.  Molecular Pathophysiology of Fragile X-Associated Tremor/Ataxia Syndrome and Perspectives for Drug Development.

Authors:  Teresa Botta-Orfila; Gian Gaetano Tartaglia; Aubin Michalon
Journal:  Cerebellum       Date:  2016-10       Impact factor: 3.847

Review 7.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

8.  Two FMR1 premutation cases without nuclear inclusions.

Authors:  Verónica Martínez-Cerdeño; Mirna Lechpammer; Paul J Hagerman; Randi Hagerman
Journal:  Mov Disord       Date:  2017-06-01       Impact factor: 10.338

Review 9.  Noncoding RNAs in neurodegeneration.

Authors:  Evgenia Salta; Bart De Strooper
Journal:  Nat Rev Neurosci       Date:  2017-08-17       Impact factor: 34.870

Review 10.  Fragile X-associated tremor/ataxia syndrome - features, mechanisms and management.

Authors:  Randi J Hagerman; Paul Hagerman
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.